Protease-activated drug development

Ki Young Choi, Magdalena Swierczewska, Seulki Lee, Xiaoyuan Chen

Research output: Contribution to journalArticle

Abstract

In this extensive review, we elucidate the importance of proteases and their role in drug development in various diseases with an emphasis on cancer. First, key proteases are introduced along with their function in disease progression. Next, we link these proteases as targets for the development of prodrugs and provide clinical examples of protease-activatable prodrugs. Finally, we provide significant design considerations needed for the development of the next generation protease-targeted and protease-activatable prodrugs.

Original languageEnglish (US)
Pages (from-to)156-179
Number of pages24
JournalTheranostics
Volume2
Issue number2
DOIs
StatePublished - 2012
Externally publishedYes

Fingerprint

Peptide Hydrolases
Prodrugs
Pharmaceutical Preparations
Disease Progression
Neoplasms

Keywords

  • Activatable probe
  • Alzheimer's disease
  • Aspartyl protease
  • Cancer
  • Caspase
  • Cathepsin
  • Kallikrein
  • MMP
  • Protease
  • PSA
  • Serine protease

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Cite this

Choi, K. Y., Swierczewska, M., Lee, S., & Chen, X. (2012). Protease-activated drug development. Theranostics, 2(2), 156-179. https://doi.org/10.7150/thno.4068

Protease-activated drug development. / Choi, Ki Young; Swierczewska, Magdalena; Lee, Seulki; Chen, Xiaoyuan.

In: Theranostics, Vol. 2, No. 2, 2012, p. 156-179.

Research output: Contribution to journalArticle

Choi, KY, Swierczewska, M, Lee, S & Chen, X 2012, 'Protease-activated drug development', Theranostics, vol. 2, no. 2, pp. 156-179. https://doi.org/10.7150/thno.4068
Choi, Ki Young ; Swierczewska, Magdalena ; Lee, Seulki ; Chen, Xiaoyuan. / Protease-activated drug development. In: Theranostics. 2012 ; Vol. 2, No. 2. pp. 156-179.
@article{811a030b744e477495bf5544e723af07,
title = "Protease-activated drug development",
abstract = "In this extensive review, we elucidate the importance of proteases and their role in drug development in various diseases with an emphasis on cancer. First, key proteases are introduced along with their function in disease progression. Next, we link these proteases as targets for the development of prodrugs and provide clinical examples of protease-activatable prodrugs. Finally, we provide significant design considerations needed for the development of the next generation protease-targeted and protease-activatable prodrugs.",
keywords = "Activatable probe, Alzheimer's disease, Aspartyl protease, Cancer, Caspase, Cathepsin, Kallikrein, MMP, Protease, PSA, Serine protease",
author = "Choi, {Ki Young} and Magdalena Swierczewska and Seulki Lee and Xiaoyuan Chen",
year = "2012",
doi = "10.7150/thno.4068",
language = "English (US)",
volume = "2",
pages = "156--179",
journal = "Theranostics",
issn = "1838-7640",
publisher = "Ivyspring International Publisher",
number = "2",

}

TY - JOUR

T1 - Protease-activated drug development

AU - Choi, Ki Young

AU - Swierczewska, Magdalena

AU - Lee, Seulki

AU - Chen, Xiaoyuan

PY - 2012

Y1 - 2012

N2 - In this extensive review, we elucidate the importance of proteases and their role in drug development in various diseases with an emphasis on cancer. First, key proteases are introduced along with their function in disease progression. Next, we link these proteases as targets for the development of prodrugs and provide clinical examples of protease-activatable prodrugs. Finally, we provide significant design considerations needed for the development of the next generation protease-targeted and protease-activatable prodrugs.

AB - In this extensive review, we elucidate the importance of proteases and their role in drug development in various diseases with an emphasis on cancer. First, key proteases are introduced along with their function in disease progression. Next, we link these proteases as targets for the development of prodrugs and provide clinical examples of protease-activatable prodrugs. Finally, we provide significant design considerations needed for the development of the next generation protease-targeted and protease-activatable prodrugs.

KW - Activatable probe

KW - Alzheimer's disease

KW - Aspartyl protease

KW - Cancer

KW - Caspase

KW - Cathepsin

KW - Kallikrein

KW - MMP

KW - Protease

KW - PSA

KW - Serine protease

UR - http://www.scopus.com/inward/record.url?scp=84864572139&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864572139&partnerID=8YFLogxK

U2 - 10.7150/thno.4068

DO - 10.7150/thno.4068

M3 - Article

C2 - 22400063

AN - SCOPUS:84864572139

VL - 2

SP - 156

EP - 179

JO - Theranostics

JF - Theranostics

SN - 1838-7640

IS - 2

ER -